|
|
|
|
Mitoxantrone 12 mg/m2 was generally well tolerated and reduced progression of disability and clinical exacerbations. Further studies are needed to identify the patients with these forms of multiple sclerosis who are most likely to respond t o therapy, the best treatment protocols, and the frequency of long-term drug-related side-effects. |
|